South Korea's Daewoong Pharmaceutical announced on Monday that it exported its technology for clinical development and commercialization rights of its DWJ108U Depot injection (Leuprolide) product in the US to a UAE-based Zydus Worldwide DMCC.
The contract is worth $92.38 million, representing 9.55% of Daewoong's 2022 sales. The development and commercialization milestone is $25.5 million, and the supply contract amount is $66.88 million.
Under this contract, Daewoong Pharmaceutical will transfer the joint development, product approval, and commercialization rights of DWJ108U depot injection to Zydus for the US region.
Zydus is scheduled to conduct US clinical trials of DWJ108U depot injection and will begin commercialization after receiving product approval from the US Food and Drug Administration (FDA).
Daewoong Pharmaceutical, a leading South Korean pharmaceutical company will export its new diabetes drug Envlo Tab. (active ingredient:enavogliflozin), to Russia and the Commonwealth of Independent States (CIS). The company revealed on Friday that it has finalized a contract with JSC Pharmasyn
South Korea's Daewoong Pharmaceutical announced on Tuesday it signed with memorandum of understanding (MOU) with Merck Life Science to build an artificial intelligence (AI)-based new drug development platform and provide technology support the entire cycle of the development process. Merc
South Korea’s Daewoong Pharmaceutical on Wednesday said its gastroesophageal reflux (GER) disease drug Fexuclue (active ingredient fexuprazan hydrochloride) has received product approval from Mexico’s COFEPRIS, or the Federal Committee for Protection from Sanitary Risks.Mexico is t
South Korea's Daewoong Pharmaceutical is venturing into the development of a product that can easily treat diabetic retinopathy in the form of eye drops. Currently, patients with this condition need to visit an ophthalmologist and receive injections into their eyes for treatment.Daewoong
South Korea's Daewoong Pharmaceutical Co. announced on Thursday that it has received a patent from the US Patent and Trademark Office for the use of its botulinum toxin Nabota (American name: Jeuveau) in the treatment of migraines through its US partner AEON Biopharma.This patent provides excl